Propanc reports 90% tumor growth inhibition with PRP in pancreatic cancer models, contrasting with Revolution Medicines’ daraxonrasib
PPCB•Propanc Biopharma reported data showing 90% tumor growth inhibition with PRP in pancreatic cancer models and a marked reduction in metastatic burden. The company plans to start an open-label Phase 1b study in Q1 2027, enrolling up to 50 patients.
1. Study data and plans
Propanc Biopharma reported that PRP showed 90% tumor growth inhibition and a marked reduction in metastatic burden in pancreatic ductal adenocarcinoma models. The company plans to start an open-label Phase 1b study of PRP in Q1 2027, enrolling up to 50 patients.
